When you fill a prescription for a generic drug, it seems simple: the pharmacy gives you pills, your insurance covers part of it, and you pay the rest. But behind that transaction, there’s a hidden system that rarely gets talked about - and it’s not working the way most people think. Generics make up 90% of all prescriptions filled in the U.S., yet they account for only about 23% of total drug spending. That’s because they don’t work like brand-name drugs when it comes to how insurance pays for them. No big rebates. No complex negotiations. Just a quiet, confusing system that often leaves insurers - and you - paying more than you realize.
Generics Don’t Get Rebates (And That’s the Point)
Most people assume all drugs get rebates. That’s not true. Brand-name drugs? Yes. Generics? Almost never. Why? Because rebates are designed to create competition among manufacturers who charge the same high list price. When multiple companies sell similar brand-name drugs, the one offering the biggest rebate to the pharmacy benefit manager (PBM) gets placed on the insurance plan’s preferred list. That’s how PBMs keep costs down - by playing manufacturers against each other. But generics? There’s no such game. Hundreds of companies make the exact same drug - let’s say lisinopril for high blood pressure. No one has a patent. No one has exclusive rights. The price is set by supply and demand, not by who offers the biggest kickback. So instead of rebates, PBMs negotiate flat prices. That sounds fair, right? But here’s where it gets messy.What Insurance Actually Pays: The Spread Pricing Trap
Here’s the reality: when your insurance pays for a generic, it’s not paying what the pharmacy pays. It’s paying what the PBM says it should pay - and that number is often inflated. How? Through something called spread pricing. Let’s say the pharmacy buys a bottle of generic metformin for $3.50. The PBM tells your insurance plan: "We’ll reimburse you $8.50." So your insurer pays $8.50. But the pharmacy only gets $3.50. The $5 difference? The PBM keeps it. That’s spread pricing. It’s not a rebate. It’s a hidden markup. And it’s completely opaque. Most employers and insurers don’t even know it’s happening until they dig into their claims data. A 2023 analysis by the National Business Group on Health found that 68% of large employers couldn’t accurately determine the true cost of generics because PBMs refused to disclose acquisition prices. One Fortune 500 HR director told Becker’s Hospital Review: "We discovered our PBM was charging us $8.50 per generic prescription while paying pharmacies only $4.25. We were paying $4.25 in hidden fees - every single time."Why This Matters: Generics Are Being Pushed Aside
You’d think PBMs would love generics. They’re cheap. They work. But here’s the twist: PBMs make more money from brand-name drugs. Why? Because brand-name manufacturers offer rebates of 30% to 70% of the list price. Generics? Maybe 2% to 5% - if anything at all. So PBMs have an incentive to keep generics off the formulary. Not because they’re bad. Not because they’re unsafe. But because they don’t bring in the same kickback. A 2023 report from Rightway Healthcare found that PBMs sometimes exclude a $0.15-per-dose generic in favor of a $5-per-dose brand-name drug with a 60% rebate. The math? The insurer pays more. The patient pays more. And the PBM pockets the difference. This isn’t hypothetical. In one case documented by the Midwest Manufacturers Association, a PBM blocked a generic version of a heart medication because the brand-name drug offered a higher rebate. The result? Patients paid $200 more per month - even though the generic was chemically identical and FDA-approved.
Who’s Really Paying?
It’s easy to blame insurance companies. But they’re just as confused as you are. Most insurers don’t control their own formularies - PBMs do. And PBMs aren’t required to tell insurers how much they’re keeping from spread pricing. The Department of Labor’s 2024 report found that the average spread on generic prescriptions was $4.73 per fill. Multiply that by 10 billion generic prescriptions a year? That’s nearly $50 billion in hidden fees. And that money isn’t going to drug companies. It’s going to PBMs. Employers who self-insure are the ones who feel this the hardest. They pay the full cost of claims, so every hidden fee hits their bottom line. But even people on fully insured plans aren’t safe. When insurers pay more for drugs, they raise premiums. So you’re paying for it too - through your monthly bill.The System Is Changing - Slowly
There’s growing pressure to fix this. The Biden administration’s 2024 Executive Order directed the Department of Health and Human Services to examine practices that limit generic use. The No Surprises Act of 2020 pushed for more transparency, but it didn’t go far enough. And in March 2025, CMS announced new Medicare drug price negotiations - but guess what? Generics were excluded. Again. Still, change is happening. In 2020, only 18% of large employers used pass-through pricing for generics - where PBMs charge a flat administrative fee and don’t keep the spread. By 2024, that number jumped to 42%. That’s progress. And the Employee Benefit Research Institute predicts that by 2026, federal legislation will require PBMs to disclose the true acquisition cost of every generic drug.
What You Can Do
If you’re an employer or plan sponsor, demand transparency. Ask your PBM: "What do you pay pharmacies for the top 10 generics we use?" If they won’t tell you, it’s time to switch. If you’re a patient, check your copay. If your generic costs more than $10 at the pharmacy, ask your doctor if there’s a cheaper alternative - and whether your plan has a preferred pharmacy. Sometimes, mail-order or specialty pharmacies offer better prices. And if you’re confused? You’re not alone. The system is designed to be confusing. But the truth is simple: generics should be the cheapest option. Right now, they’re not. And that’s not because of the drugs. It’s because of the middlemen.Do generic drugs have rebates like brand-name drugs?
Generally, no. Generic drugs rarely have rebates because they’re already priced competitively by multiple manufacturers. Unlike brand-name drugs, where companies offer 30-70% rebates to get on formularies, generics operate on flat pricing. Any rebate offered is usually under 5% - if at all.
Why do insurers pay more for generics than pharmacies charge?
Because of spread pricing. Pharmacy benefit managers (PBMs) set a reimbursement rate to insurers that’s higher than what they actually pay pharmacies. The difference - often $4 to $5 per prescription - is kept by the PBM as profit. This isn’t disclosed in most insurance contracts.
Can PBMs block generic drugs from insurance plans?
Yes. PBMs sometimes exclude low-cost generics to favor higher-priced brand-name drugs that offer bigger rebates. This creates a perverse incentive: the cheapest drug isn’t always the one covered. In some cases, patients have to appeal or pay out-of-pocket to get a generic they need.
How much do PBMs make from generic drug spread pricing?
The average spread on generic prescriptions is $4.73 per fill, according to the U.S. Department of Labor (2024). With over 10 billion generic prescriptions filled annually in the U.S., that adds up to nearly $50 billion in hidden fees going to PBMs each year.
Are generics excluded from Medicare drug price negotiations?
Yes. The Inflation Reduction Act of 2022 explicitly excludes generic drugs and biosimilars from Medicare’s drug price negotiation program. The law assumes competition among manufacturers keeps generic prices low - but it doesn’t account for hidden PBM fees that inflate what insurers and patients actually pay.
What’s the difference between WAC, AWP, and net price for generics?
Wholesale Acquisition Cost (WAC) is what manufacturers charge pharmacies. Average Wholesale Price (AWP) is an outdated list price used as a billing benchmark - often inflated. Net price is what the insurer actually pays after any discounts or rebates. For generics, net price is usually close to WAC - but spread pricing makes it look like the insurer paid much more.